Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium - 15/03/17

Doi : 10.1016/S1470-2045(17)30026-8

Roderick Skinner, ProfPhD ^a,^⁎ , Renee L Mulder, PhD ^c, Leontien C Kremer, PhD ^c, Melissa M Hudson, ProfMD ^d, Louis S Constine, ProfMD ^f, Edit Bardi, PhD ^g,^h, Annelies Boekhout, PhD ⁱ, Anja Borgmann-Staudt, MD ^j, Morven C Brown, MSc ^b, Richard Cohn, ProfFRACP ^k, Uta Dirksen, ProfMD ^l, Alexsander Giwercman, ProfMD ^m, Hiroyuki Ishiguro, MD ⁿ, Kirsi Jahnukainen, PhD ^o, Lisa B Kenney, ProfMD ^p, Jacqueline J Loonen, PhD ^q, Lilian Meacham, ProfMD ^r, Sebastian Neggers, PhD ^s, Stephen Nussey, ProfDPhil ^t, Cecilia Petersen, PhD ^u, Margarett Shnorhavorian, MD ^v, Marry M van den Heuvel-Eibrink, ProfMD ^w, Hanneke M van Santen, MD ^x, William H B Wallace, ProfMD ^y, Daniel M Green, ProfMD ^e

^a Department of Paediatric and Adolescent Haematology/Oncology and Children’s Haemopoietic Stem Cell Transplant Unit, Great North Children’s Hospital and Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK

^b Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK

^c Department of Pediatric Oncology, Emma Children’s Hospital, Academic Medical Center, Amsterdam, Netherlands

^d Department of Oncology, St Jude Children’s Research Hospital, Memphis, TN, USA

^e Departments of Oncology and Epidemiology and Cancer Control, St Jude Children’s Research Hospital, Memphis, TN, USA

^f Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, NY, USA

^g 2nd Department of Pediatrics, Semmeilweis University, Budapest, Hungary

^h Hungary and Johannes Kepler Universitätsklinikum, Linz, Austria

ⁱ Department of Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, Netherlands

^j Department of Paediatric Haematology, Oncology and Haemopoietic Stem Cell Transplantation, Charité-Universitätsmedizin, Berlin, Germany

^k Kids Cancer Centre, Sydney Children’s Hospital, Sydney and UNSW Medicine, Sydney, NSW, Australia

^l Department of Paediatric Haematology and Oncology, University Hospital Muenster, Muenster, Germany

^m Department of Translational Medicine, Lund University, Malmö, Sweden

ⁿ Department of Pediatrics, Tokai University School of Medicine, Isehara, Japan

^o Division of Hematology-Oncology and Stem Cell Transplantation, Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

^p Department of Pediatric Oncology, Dana-Farber/Boston Children’s Cancer and Blood Disorder Center, Harvard Medical School, Boston, MA, USA

^q Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands

^r Department of Pediatrics, Division of Hematology/Oncology and Endocrinology, Emory University and Aflac Cancer Center of Children’s Healthcare of Atlanta, Atlanta, GA, USA

^s Department of Medicine section Endocrinology, Erasmus University Medical Center Rotterdam and Pediatric Oncology, Sophia’s Children’s Hospital/Erasmus University Medical Center, Rotterdam, Netherlands

^t Department of Endocrinology, St George’s University of London, London, UK

^u Department of Pediatric Oncology, Karolinska University Hospital, Stockholm, Sweden

^v Department of Urology, University of Washington, Division of Pediatric Urology, Seattle Children’s Hospital, Seattle, WA, USA

^w Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands

^x Department of Pediatric Endocrinology, Wilhelmina Kinderziekenhuis, Universitair Medisch Centrum Utrecht, Utrecht, Netherlands

^y University of Edinburgh and Royal Hospital for Sick Children, Edinburgh, UK

^* Correspondence to: Prof R Skinner, Department of Paediatric and Adolescent Haematology/Oncology and Children’s Haemopoietic Stem Cell Transplant Unit, Great North Children’s Hospital, Newcastle upon Tyne NE1 4LP, UK Correspondence to: Prof R Skinner Department of Paediatric and Adolescent Haematology/Oncology and Children’s Haemopoietic Stem Cell Transplant Unit Great North Children’s Hospital Newcastle upon Tyne NE1 4LP UK

Summary

Treatment with chemotherapy, radiotherapy, or surgery that involves reproductive organs can cause impaired spermatogenesis, testosterone deficiency, and physical sexual dysfunction in male pubertal, adolescent, and young adult cancer survivors. Guidelines for surveillance and management of potential adverse effects could improve cancer survivors’ health and quality of life. Surveillance recommendations vary considerably, causing uncertainty about optimum screening practices. This clinical practice guideline recommended by the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium, developed using evidence-based methodology, critically synthesises surveillance recommendations for gonadotoxicity in male childhood, adolescent, and young adult (CAYA) cancer survivors. The recommendations were developed by an international multidisciplinary Panel including 25 experts in relevant medical specialties, using a consistent and transparent process. Recommendations were graded according to the strength of underlying evidence and potential benefit gained by early detection and appropriate management. The aim of the recommendations is to enhance evidence-based care for male CAYA cancer survivors. The guidelines reveal the paucity of high-quality evidence, highlighting the need for further targeted research.

Le texte complet de cet article est disponible en PDF.

Plan

Introduction

Aim of the study

Methods

Search strategy and selection criteria

Definitions used

Final recommendations

Findings

Impaired spermatogenesis

Testosterone deficiency

Physical sexual dysfunction

Discussion

Export

Vol 18 - N° 2

P. e75-e90 - février 2017 Retour au numéro

Article précédent

Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial
Csaba Polgár, Oliver J Ott, Guido Hildebrandt, Daniela Kauer-Dorner, Hellen Knauerhase, Tibor Major, Jaroslaw Lyczek, José Luis Guinot, Jürgen Dunst, Cristina Gutierrez Miguelez, Pavel Slampa, Michael Allgäuer, Kristina Lössl, Bülent Polat, György Kovács, Arnt-René Fischedick, Rainer Fietkau, Alexandra Resch, Anna Kulik, Leo Arribas, Peter Niehoff, Ferran Guedea, Annika Schlamann, Richard Pötter, Christine Gall, Wolfgang Uter, Vratislav Strnad, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO)

| Article suivant

Prevention of radiotherapy-induced neurocognitive dysfunction in survivors of paediatric brain tumours: the potential role of modern imaging and radiotherapy techniques
Thankamma Ajithkumar, Stephen Price, Gail Horan, Amos Burke, Sarah Jefferies

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium - 15/03/17

Summary

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL